Amgen advances MariTide obesity drug into Phase 3 MARITIME program

Amgen

Amgen

AMGN

0.00
  • Amgen highlighted progress on investigational obesity drug maridebart cafraglutide (MariTide), engineered to block GIP receptor signaling while activating GLP-1 pathway.
  • Program was shaped by human genetics work with deCODE Genetics that identified GIP receptor blockade as a promising strategy, supporting the dual-mechanism design.
  • Company positioned MariTide as a long-acting antibody-peptide conjugate that could support monthly or less frequent dosing, a potential differentiator in obesity treatment.
  • Asset is being evaluated in Phase 3 MARITIME development program for obesity and obesity-related conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.